Results 11 to 20 of about 157,428 (296)

Mutations and insights into the molecular mechanisms of resistance of Mycobacterium tuberculosis to first-line [PDF]

Genetics and Molecular Biology, 2023
Genetically antimicrobial resistance in Mycobacterium tuberculosis is currently one of the most important aspects of tuberculosis, considering that there are emerging resistant strains for almost every known drug used for its treatment.
Nicolas de Oliveira Rossini, Marcio Vinicius Bertacine Dias   +1 more
doaj   +1 more source

Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda

The Lancet Microbe, 2020
Summary: Background: The Xpert MTB/RIF (Xpert) assay is used globally to rapidly diagnose tuberculosis and resistance to rifampicin. We investigated the frequency and predictors of false-positive findings of rifampicin resistance with Xpert. Methods: We
Jean Claude Semuto Ngabonziza, MSc, Tom Decroo, PhD, Patrick Migambi, MSc, Yves Mucyo Habimana, MD, Armand Van Deun, PhD, Conor J Meehan, PhD, Gabriela Torrea, PhD, Faridath Massou, PharmD, Willem Bram de Rijk, BS, Bertin Ushizimpumu, BS, Esdras Belamo Niyigena, BS, Emil Ivan, PhD, Jules Mugabo Semahore, MD, Jean Baptiste Mazarati, PhD, Corinne Simone Merle, PhD, Philip Supply, PhD, Dissou Affolabi, ProfPhD, Leen Rigouts, PhD, Bouke Catherine de Jong, ProfPhD   +18 more
doaj   +1 more source

Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy [PDF]

, 2016
Post-exposure prophylaxis (PEP) for leprosy is administered as one single dose of rifampicin (SDR) to the contacts of newly diagnosed leprosy patients. SDR reduces the risk of developing leprosy among contacts by around 60 % in the first 2-3 years after ...
Anthony, Richard, Bratschi, Martin W., Cambau, Emmanuelle, Cavaliero, Arielle, Kasang, Christa, Mieras, Liesbeth, Perera, Geethal, Reichman, Lee, Richardus, Jan Hendrik, Saunderson, Paul, Steinmann, Peter, van Brakel, Wim, van den Broek, Jacques, Yew, Wing Wai   +13 more
core   +10 more sources

Biodegradable and Bioactive Carriers Based on Poly(betulin disuccinate-co-sebacic Acid) for Rifampicin Delivery

Pharmaceutics, 2022
This paper describes the preparation and characterization of polymer-drug systems based on polymeric microspheres obtained from poly(betulin disuccinate-co-sebacic acid).
Daria Niewolik, Barbara Bednarczyk-Cwynar, Piotr Ruszkowski, Alicja Kazek-Kęsik, Grzegorz Dzido, Katarzyna Jaszcz   +5 more
doaj   +1 more source

The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in Staphylococcus aureus

Antibiotics, 2022
Corallopyronin A (CorA) is active against Gram-positive bacteria and targets the switch region of RNA polymerase. Because of the high frequency of mutation (FoM) leading to rifampicin resistance, we determined the CorA FoM in S.
Jan Balansky, Kenneth Pfarr, Christiane Szekat, Stefan Kehraus, Tilman Aden, Miriam Grosse, Rolf Jansen, Thomas Hesterkamp, Andrea Schiefer, Gabriele M. König, Marc Stadler, Achim Hoerauf, Gabriele Bierbaum   +12 more
doaj   +1 more source

Cell membrane components of Brucella melitensis play important roles in the resistance of low-level rifampicin.

PLoS Neglected Tropical Diseases, 2020
Brucella spp. are facultative intracellular pathogens that can persistently colonize host cells and cause the zoonosis- brucellosis. The WHO recommended a treatment for brucellosis that involves a combination of doxycycline, rifampicin, or streptomycin ...
Xiaowen Yang, Tonglei Wu, Wenxiao Liu, Guozhong Tian, Hongyan Zhao, Dongri Piao, Hai Jiang, Qingmin Wu   +7 more
doaj   +1 more source

Competitive selection of lactic acid bacteria that persist in the human oral cavity [PDF]

, 2011
Lactic acid bacteria (LAB) might offer opportunities as oral probiotics provided candidate strains persist in the mouth. After intake of a mixture of 69 LAB, strains of Lactobacillus fermentum and Lactobacillus salivarius were especially recovered ...
Snel, J., Marco, M.L., Kingma, F., Noordman, W.M., Rademaker, J., Kleerebezem, M.   +5 more
core   +2 more sources

Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. [PDF]

, 2020
BACKGROUND: Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia.
Abass, KM, Agossadou, D, Ampadu, EO, Asiedu, KB, Chauty, A, Egondi, TW, Frimpong, M, Ganlonon, L, Gateau, T, Grosset, J, Lehman, L, Macdonald, JM, Marion, E, Ochieng Otieno, M, Ohene, S-A, Omollo, R, Paintsil, A, Phillips, RO, Robert, J, Saizonou, R, Sarfo, FS, Sarpong, G, Sarpong, NF, Saunderson, P, Stienstra, Y, study team, Thompson, W, Tiendrebeogo, A, Treadwell, T, van der Werf, TS, Wansbrough-Jones, M, Wilson, T   +31 more
core   +3 more sources

Mycobacterium ulcerans infection: control, diagnosis, and treatment. [PDF]

, 2006
The skin disease Buruli ulcer, caused by Mycobacterium ulcerans, is the third most common mycobacterial disease after tuberculosis and leprosy and mainly affects remote rural African communities. Although the disease is known to be linked to contaminated
Adjei, Amofah, Amofah, Andries, Aujoulat, Bentoucha, Darie, Debacker, Debacker, Debacker, Dega, Dega, Dhople, Dhople, Dhople, Drummond, Eddyani, Eric Comte, Espey, Etuaful, Evans, Evans, Fabienne Nackers, Fehr, Françoise Portaels, Guédénon, Hospers, Huygen, Johnson, Johnson, Johnson, Kanga, Kanga, Kanga, Klutse, Marsollier, Marsollier, Marsollier, Marsollier, Marsollier, Marston, Meyers, Mve-Obiang, Nakanaga, Noeske, Okenu, Phillips, Phillips, Portaels, Pszolla, Raghunathan, Revill, Rhodes, Scott, Siegmund, Smith, Stienstra, Stienstra, Stragier, Tanghe, Thangaraj, van der Werf, van der Werf, Veitch, Vinciane Sizaire   +64 more
core   +2 more sources

Efficacy of Treatments for Cholestatic Pruritus: A Systemic Review and Meta-analysis

Acta Dermato-Venereologica, 2022
Cholestatic itch is a disabling symptom that may be secondary to liver or biliary diseases. Management of cholestatic pruritus is complex. A systematic review and meta-analysis on the efficacy of treatments for cholestatic pruritus were performed. PubMed
Charles Dervout, Nicholas Boulais, Thomas Barnetche, Jean-Baptiste Nousbaum, Emilie Brenaut, Laurent Misery   +5 more
doaj   +1 more source